FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * BIRD JEFFREY W 2. Issuer Name and Ticker or Trading Symbol PORTOLA PHARMACEUTICALS INC [ PTLA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
755 PAGE MILL ROAD, SUITE A-200
3. Date of Earliest Transaction (MM/DD/YYYY)
7/2/2020
(Street)
PALO ALTO, CA 94304-1005
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  7/2/2020    D    20475.0000  D(1) $18.0000  0.0000  D (2)  
Common Stock  7/2/2020    D    10007.0000  D(1) $18.0000  0.0000  I  By Ltd Liability Company (SHM) (3)
Common Stock  7/2/2020    D    45402.0000  D(1) $18.0000  0.0000  I  By Ltd Partnership (NEST) (4)
Common Stock  7/2/2020    D    458569.0000  D(1) $18.0000  0.0000  I  By Trust (Trustees) (5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $24.1900  7/2/2020    D        6000.0000    (6) 6/1/2026  Common Stock  6000.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $19.7400  7/2/2020    D        14101.0000    (6) 6/4/2023  Common Stock  14101.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $42.8100  7/2/2020    D        6000.0000    (6) 6/7/2028  Common Stock  6000.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $26.0900  7/2/2020    D        6991.0000    (6) 6/12/2029  Common Stock  6991.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $17.9400  7/2/2020    D        11377.0000    (7) 6/12/2030  Common Stock  11377.0000   (7) 0.0000  D (2)  
Stock Option (Right to Buy)  $44.3900  7/2/2020    D        10000.0000    (6) 6/16/2025  Common Stock  10000.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $35.0600  7/2/2020    D        6000.0000    (6) 6/16/2027  Common Stock  6000.0000   (6) 0.0000  D (2)  
Stock Option (Right to Buy)  $29.1900  7/2/2020    D        10000.0000    (6) 6/27/2024  Common Stock  10000.0000   (6) 0.0000  D (2)  

Explanation of Responses:
(1)  Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
(2)  The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.
(3)  Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
(4)  Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.
(5)  Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
(6)  In connection with the Merger, these options were canceled without payment.
(7)  At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BIRD JEFFREY W
755 PAGE MILL ROAD, SUITE A-200
PALO ALTO, CA 94304-1005
X



Signatures
/s/ Robert Yin, by power of attorney 7/6/2020
**Signature of Reporting Person Date
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Portola Pharmaceuticals Charts.
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Portola Pharmaceuticals Charts.